Protected T-cells persist and proliferate in HIV gene therapy study
The 'Boston patients' experience HIV rebound after stem cell transplants
HIV attachment inhibitor BMS-663068 shows good safety and efficacy in phase 2b study
Monkey studies confirm viability of injectable PrEP drug
Short course of ART during primary HIV infection has immunological and virological benefits after treatment is stopped
Progress towards an HIV cure
Once-daily raltegravir effective as maintenance therapy
Dolutegravir matches or surpasses other regimens for first-line HIV treatment
Future HIV care will include both novel antiretroviral drugs and new treatment strategies
